Valuation: ARYx Therapeutics, Inc.

Market Cap 90.35L 79.03L 72.89L 67.32L 1.28Cr 86Cr 1.3Cr 8.71Cr 3.42Cr 42Cr 3.39Cr 3.32Cr 145.93Cr P/E 2008
-1.76x
P/E 2009 -2.66x
Enterprise Value 1.14Cr 99.77L 92.02L 84.99L 1.61Cr 108.78Cr 1.64Cr 11Cr 4.32Cr 54Cr 4.28Cr 4.19Cr 184.23Cr EV / Sales 2008
40,19,605x
EV / Sales 2009 -
Free-Float
100%
Yield 2008 *
-
Yield 2009 -
Change 5-day change 1-year change 3-year change Capi.($)
+47.06%+4.62% - - 33
-2.48%-3.13%+55.85%+89.65% 5.49TCr
-0.55%-6.57%+55.85%+128.31% 5.46TCr
-5.09%-1.69%+7.63%+422.94% 2.51TCr
-0.45%-2.82%-17.77%-16.65% 2.31TCr
-1.69%-0.64%+40.04%-0.48% 1.99TCr
+1.87%+4.16%+38.74%-26.42% 1.75TCr
-2.72%-0.60%+187.08%+351.91% 1.65TCr
-2.42%+1.00%+48.24%+635.77% 1.57TCr
-1.19%+0.50%+22.44%+188.42% 1.42TCr
Average +3.23%-0.82%+48.68%+197.05% 2.68TCr
Weighted average by Cap. -1.68%-1.56%+47.76%+166.27%

Financials

2008 2009
Net sales 19.72 17.25 15.91 14.7 27.89 1.88T 28.36 190.14 74.67 926.72 74.06 72.45 3.19T -
Net income -3.12Cr -2.73Cr -2.52Cr -2.33Cr -4.41Cr -297.74Cr -4.49Cr -30Cr -12Cr -146.68Cr -12Cr -11Cr -504.24Cr -3.32Cr -2.9Cr -2.68Cr -2.47Cr -4.69Cr -316.33Cr -4.77Cr -32Cr -13Cr -155.83Cr -12Cr -12Cr -535.72Cr
Net Debt -29.9 -26.16 -24.13 -22.28 -42.28 -2.85T -42.99 -288.28 -113.21 -1.41T -112.28 -109.84 -4.83T 2.37 2.07 1.91 1.77 3.35 226.13 3.41 22.86 8.98 111.4 8.9 8.71 382.97
Logo ARYx Therapeutics, Inc.
ARYx Therapeutics, Inc. is a United States-based pharmaceutical Company. The Company is developing a proprietary portfolio of patient-targeted, first-in-class monoclonal antibodies designed to treat seriously ill patients with difficult-to-treat diseases. It is engaged in retrometabolic drug design that focuses on the safety of oral therapies for chronic disease. The Companys clinical compounds include naronapride (ATI-7505) for gastrointestinal disorders; budiodarone (ATI-2042, for the treatment of atrial fibrillation; tecarfarin (ATI-5923) for the treatment of anticoagulation; and ATI-9242, for psychiatric disorders.
Employees
-